ClinicalTrials.gg
CompletedNCT04807348Updated Jul 15, 2024

Chiglitazar Added to Metformin for Type 2 Diabetes

A Phase 3 interventional study of Chiglitazar 32mg and Chiglitazar 48mg in Type 2 Diabetes, sponsored by Chipscreen Biosciences, Ltd.. Completed at 50 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-15.

Sponsored by Chipscreen Biosciences, Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
533
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 909 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 228 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Enrollment
159th of 767
533 · median 199
Started
2021
with 56 others
Phase 3
207 of 909
38 open now
Registered
455th of 909
by date

Among the 909 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 159th largest by enrollment of the 767 interventional ones that give a count, is one of 57 that started in 2021, is one of 207 in phase 3, and was the 455th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 909 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

The purpose of the trial is to evaluate the effect of Chiglitazar added to metformin to type 2 diabetes Inadequately controlled with metformin Monotherapy.

Read the detailed description

This clinical trial is a multi-center, randomized, double-blind, placebo parallel control design, and uses superiority test to determine whether the experimental group is superior to the control group in terms of main efficacy endpoints.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ) Provide a signed and dated form;
  2. ) Men and women aged ≥ 18 years and ≤ 75 years;
  3. ) According to the World Health Organization ( the WHO ) 1999 criteria for the diagnosis of type 2 diabetes;
  4. ) After metformin stable dose monotherapy (≥1500 mg/day or maximum tolerated dose, but the maximum tolerated dose not \< l000 mg/day) for at least 8 weeks;
  5. ) The local value during the screening period: 7.5% ≤ HbA1c ≤ 11% ;
  6. ) The HbA1c value of the central laboratory before randomization: 7.0% ≤ HbA1c ≤ 10.5% ;
  7. ) ≥ 18.5 kg/m2 and ≤ 35 kg/m 2 ;
  8. ) Fasting C- peptide ≥ 0.5 nmol/L ;
  9. ) Women of ( WOCBP ) should take reliable measures at least 1 month before the screening, during the entire trial, and within 3 months after completing the trial; male subjects should take reliable contraceptive measures to avoid making their sexual partners to pregnant during the entire trial and within 3 months after the trial.

Exclusion criteria

Exclusion Criteria:

  1. ) Type 1 diabetes;
  2. ) Pregnancy or lactation;
  3. ) The (NYHA ) defines congestive heart failure as grade III or IV ;
  4. ) Significant history of cardiovascular and cerebrovascular diseases within 6 months before screening, defined as myocardial infarction, coronary artery bypass graft or angioplasty, valvular disease or repair, unstable angina, transient brain Ischemic attack, or cerebrovascular accident;
  5. ) Suffered from malignant tumors (except cured basal cell carcinoma) within 5 years before screening;
  6. ) Edema of lower limbs or edema of the whole body;
  7. ) Moderate to severe renal insufficiency [ Calculated \<60 ml/ ( min*1.73m2 ) using CKD - EPI formula ];
  8. ) urinary albumin-to-creatinine ratio of > 300 mg /g;
  9. ) Triglyceride> 5.6 mmol /L;
  10. ) Active liver disease and /or obvious liver function abnormalities, defined as >2.5 times the value and/or ALT>2.5 times the upper limit of normal value and/or total >1.5 times the normal value Upper limit
  11. ) arrhythmias in the examination and treatment or intervention are required. The investigator judges that it is not suitable to participate in this clinical trial;
  12. ) (HIV) antibody-positive; Treponema pallidum antibody positive; positive surface antigen and HBV DNA quantification values were higher than the upper; antibodies and HCV RNA quantification values were higher than the upper ;
  13. ) History of illegal drug abuse within 12 months before screening ;
  14. ) Participated in other clinical trials within 90 days before screening ;
  15. ) Donated whole blood, plasma, or within 3 months before screening.
  16. ) Before randomization, the investigator judged that the subjects had poor compliance with the study protocol or drug treatment, defined as the subjects taking less than 80% or more than 120% of the prescribed dose of chiglitazar/ placebo or metformin;
  17. ) The investigator judged that it is not suitable to participate in this clinical trial.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
533 participants (actual)

Study arms

  • Experimental
    Chiglitazar sodium 32mg QD+metformin

    Chiglitazar 32mg qd+metformin

    Drug: Chiglitazar 32mg · Drug: Metformin Hydrochloride

  • Experimental
    Chiglitazar sodium 48 mg QD+metformin

    Chiglitazar 48 mg qd+metformin

    Drug: Chiglitazar 48mg · Drug: Metformin Hydrochloride

  • Placebo comparator
    placebo+metformin

    placebo+metformin

    Drug: Placebo · Drug: Metformin Hydrochloride

Interventions

  • Administrated once daily

    Also known as: Bilessglu, CS038

  • Administrated once daily

    Also known as: Bilessglu, CS038

  • DrugPlacebo

    Placebo of Chiglitazar

    Also known as: Chiglitazar simulator

  • most tolerable dose

    Also known as: Glucophage

06

What researchers measure

Primary outcomes

  1. percentage of HbA1c change from baseline

    central lab test

    Time frame: 24 weeks

Secondary outcomes

  1. Changes in blood fasting plasma glucose level from baseline

    central lab test

    Time frame: 12 and 24 weeks

  2. Changes of HOMA-the IR value from baseline

    model calculated

    Time frame: 12 and 24 weeks

  3. Changes of blood lipids level from baseline

    includeing TC, LDL-C, HDL-C, VLDL-C, non-HDL-C, TG, FFA, ApoA1, ApoB

    Time frame: 12 and 24 weeks

  4. percentage of AEs

    safety

    Time frame: 28 weeks

  5. number of participants with lab abnormality

    number or rate of founds in lab tests

    Time frame: 24 weeks

07

Study locations

50 sites
  • Hefei Second People's Hospital
    Hefei, Anhui, China
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui, China
  • The Second Affiliated Hospital of Anhui Medical University
    Hefei, Anhui, China
  • Yijishan Hospital of Wannan Medical College
    Wuhu, Anhui, China
  • Beijing Chaoyang Hospital, Capital Medical University
    Beijing, Beijing, China
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing, China
  • Beijing Luhe Hospital, Capital Medical University
    Beijing, Beijing, China
  • Beijing Tongren Hospital, Capital Medical University
    Beijing, Beijing, China
  • Beijing Tsinghua Chang Gung Memorial Hospital
    Beijing, Beijing, China
  • Beijing University First Hospital
    Beijing, Beijing, China
  • Chinese People's Liberation Army Rocket Army Characteristic Medical Center
    Beijing, Beijing, China
  • Peking University People's Hospital
    Beijing, Beijing, China
  • Xuanwu Hospital, Capital Medical University
    Beijing, Beijing, China
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing, China
  • Three Gorges Hospital Affiliated to Chongqing University
    Wanzhou, Chongqing, China
  • Shenzhen People's Hospital
    Shenzhen, Guangdong, China
  • Union Shenzhen Hospital of Huazhong University of Science and Technology
    Shenzhen, Guangdong, China
  • Harrison International Peace Hospital
    Hengshui, Hebei, China
  • The Second Hospital of Hebei Medical University
    Shijia Zhuang, Hebei, China
  • The Third Hospital of Hebei Medical University
    Shijia Zhuang, Hebei, China
  • Huaihe Hospital of Henan University
    Kaifeng, Henan, China
  • The First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan, China
  • The Third People's Hospital of Luoyang City
    Luoyang, Henan, China
  • Xinxiang Central Hospital
    Xinxiang, Henan, China
  • The First People's Hospital of Chenzhou City
    Chenzhou, Hunan, China
  • Yueyang Second People's Hospital
    Yueyang, Hunan, China
  • Zhuzhou Central Hospital
    Zhuzhou, Hunan, China
  • Inner Mongolia Baotou Steel Hospital
    Baotou, Inner Mongolia, China
  • The First People's Hospital of Huai'an
    Huaian, Jiangsu, China
  • Jiangsu Provincial People's Hospital
    Nanjing, Jiangsu, China
  • Nanjing First Hospital
    Nanjing, Jiangsu, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu, China
  • Yifu Hospital Affiliated to Nanjing Medical University
    Nanjing, Jiangsu, China
  • Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu, China
  • The First Hospital of Jilin University
    Harbin, Jilin, China
  • The Fourth Affiliated Hospital of Harbin Medical University
    Harbin, Jilin, China
  • The Second Hospital of Jilin University
    Harbin, Jilin, China
  • Panjin Liaoyou Baoshihua Hospital
    Panjin, Liaoning, China
  • Jinan Central Hospital
    Jinan, Shandong, China
  • Qilu Hospital of Shandong University
    Jinan, Shandong, China
  • Affiliated Hospital of Jining Medical College, Shandong Province
    Jining, Shandong, China
  • Qingdao University Hospital
    Qingdao, Shandong, China
  • Gongli Hospital, Pudong New Area, Shanghai
    Shanghai, Shanghai, China
  • Shanghai Minhang District Central Hospital
    Shanghai, Shanghai, China
  • Shanghai Pudong Hospital
    Shanghai, Shanghai, China
  • Shanghai Seventh People's Hospital
    Shanghai, Shanghai, China
  • Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai, China
  • Central Hospital of Yuncheng City, Shanxi Province
    Yuncheng, Shanxi, China
  • Tangshan Workers' Hospital
    Tangshan, Tianjin, China
  • Huzhou Central Hospital
    Huzhou, Zhejiang, China
08

References and documents

Publications

  • Ji L, Song W, Fang H, Li W, Geng J, Wang Y, Guo L, Cai H, Yang T, Li H, Yang G, Li Q, Liu K, Li S, Liu Y, Shi F, Li X, Gao X, Tian H, Ji Q, Su Q, Zhou Z, Wang W, Zhou Z, Li X, Xu Y, Ning Z, Cao H, Pan D, Yao H, Lu X, Jia W. Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP). Sci Bull (Beijing). 2021 Aug 15;66(15):1571-1580. doi: 10.1016/j.scib.2021.03.019. Epub 2021 Mar 23. PubMed 36654286 ↗
  • Jia W, Ma J, Miao H, Wang C, Wang X, Li Q, Lu W, Yang J, Zhang L, Yang J, Wang G, Zhang X, Zhang M, Sun L, Yu X, Du J, Shi B, Xiao C, Zhu D, Liu H, Zhong L, Xu C, Xu Q, Liang G, Zhang Y, Li G, Gu M, Liu J, Yuan G, Yan Z, Yan D, Ye S, Zhang F, Ning Z, Cao H, Pan D, Yao H, Lu X, Ji L. Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS). Sci Bull (Beijing). 2021 Aug 15;66(15):1581-1590. doi: 10.1016/j.scib.2021.02.027. Epub 2021 Feb 16. PubMed 36654287 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Feb 2023, 19 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 19 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2021
First posted
Mar 19, 2021
StartActual
Jul 6, 2021
Primary completionActual
Feb 10, 2023
CompletionActual
Feb 10, 2023
Last update
Jul 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04807348
Responsible party
Sponsor
First posted
Mar 19, 2021
Start date
Jul 6, 2021
Primary completion
Feb 10, 2023
Completion
Feb 10, 2023
Last update
Jul 15, 2024

Study contacts

Linong Ji, Prof.
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chiglitazar

Start the discussion